Alga-Produced Malaria Transmission-Blocking Vaccine Candidate Pfs25 Formulated with a Human Use-Compatible Potent Adjuvant Induces High-Affinity Antibodies That Block Plasmodium falciparum Infection of Mosquitoes
Open Access
- 1 May 2015
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 83 (5) , 1799-1808
Abstract
A vaccine to prevent the transmission of malaria parasites from infected humans to mosquitoes is an important component for the elimination of malaria in the 21st century, yet it remains neglected as a priority of malaria vaccine development. The lead candidate for Plasmodium falciparum transmission-blocking vaccine development, Pfs25, is a sexual stage surface protein that has been produced for vaccine testing in a variety of heterologous expression systems. Any realistic malaria vaccine will need to optimize proper folding balanced against cost of production, yield, and potentially reactogenic contaminants. Here Chlamydomonas reinhardtii microalga-produced recombinant Pfs25 protein was formulated with four different human-compatible adjuvants (alum, Toll-like receptor 4 [TLR-4] agonist glucopyranosal lipid A [GLA] plus alum, squalene–oil-in-water emulsion, and GLA plus squalene–oil-in-water emulsion) and compared for their ability to induce malaria transmission-blocking antibodies. Alga-produced recombinant Pfs25 plus GLA plus squalene–oil-in-water adjuvant induced the highest titer and avidity in IgG antibodies, measured using alga-produced recombinant Pfs25 as the enzyme-linked immunosorbent assay (ELISA) antigen. These antibodies specifically reacted with the surface of P. falciparum macrogametes and zygotes and effectively prevented parasites from developing within the mosquito vector in standard membrane feeding assays. Alga-produced Pfs25 in combination with a human-compatible adjuvant composed of a TLR-4 agonist in a squalene–oil-in-water emulsion is an attractive new vaccine candidate that merits head-to-head comparison with other modalities of vaccine production and administration.Keywords
This publication has 57 references indexed in Scilit:
- Alga-Produced Cholera Toxin-Pfs25 Fusion Proteins as Oral VaccinesApplied and Environmental Microbiology, 2013
- Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's AdjuvantsPLOS ONE, 2012
- Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine AdjuvantPLOS ONE, 2011
- A Research Agenda to Underpin Malaria EradicationPLOS Medicine, 2011
- A Research Agenda for Malaria Eradication: VaccinesPLOS Medicine, 2011
- A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugatesProceedings of the National Academy of Sciences, 2009
- Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51PLOS ONE, 2008
- Wheat Germ Cell-Free System-Based Production of Malaria Proteins for Discovery of Novel Vaccine CandidatesInfection and Immunity, 2008
- Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titerMalaria Journal, 2007
- Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: A strategy for enhancing immunogenicity of malaria vaccine candidatesVaccine, 2007